Molecular Partners Appoints Jörn Aldag as Chairman of the Board

12-Nov-2007

Molecular Partners AG, a pioneer in the development of a novel class of therapeutic proteins termed DARPins, has announced the appointment of Jörn Aldag as President to the Board.

Jörn Aldag is President and CEO of Evotec. After the successful IPO in 1999, he was instrumental in growing Evotec from a small technology provider to one of the leading drug discovery and development companies with a promising CNS pipeline in Europe.

Prior to Evotec, Jörn Aldag was Vice President and Finance Director of MAN Gutehoffnungshütte AG, a subsidiary of MAN AG, Munich and Business Director of Treuhandanstalt, the privatization agency for East German businesses after the reunification. Jörn Aldag is currently a Member of the Monopoly Commission of the Federal Republic of Germany. Jörn Aldag holds business degrees from the Harvard Business School and the European Business School.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances